QTRX
NASDAQQuanterix Corporation
Website
News25/Ratings12
News · 26 weeks65-36%
2025-10-262026-04-19
Mix2490d
- Insider11(46%)
- Other7(29%)
- Earnings3(13%)
- SEC Filings3(13%)
Latest news
25 items- INSIDERSEC Form 4 filed by Miller Michael Francis4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERSEC Form 4 filed by Sriram Vandana4 - Quanterix Corp (0001503274) (Issuer)
- PRAidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical OncologyNovel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer PreludeDx® and Quanterix Corporation (NASDAQ:QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager® HT platform using Opal™ chemistry. This marks a significant milestone in the clinical translation of spatial proteomics. The validation of AidaBREAST included 922 hormone receptor-positive, HER2-negative invasive breast cancer
- PRQuanterix Debuts Content Innovation Engine at AACR 2026The Content Innovation Engine brings together Akoya's spatial biology platform and Quanterix's immunoassay infrastructure to systematically unlock cancer biology and accelerate the path toward clinical application Quanterix Corporation (NASDAQ:QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration of Akoya Biosciences' spatial biology platform and Quanterix's decades of ultra-sensitive, quantitative immunoassay development from the SIMOA® technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a systematic, biology-fir
- INSIDERSEC Form 4 filed by Donnelly William P4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERSEC Form 4 filed by Mendel Scott4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERSEC Form 4 filed by Miller Michael Francis4 - Quanterix Corp (0001503274) (Issuer)
- PRQuanterix Corporation Announces Date of 2026 Annual MeetingQuanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the "Company"), today announced that the Company's 2026 annual meeting of shareholders (the "Annual Meeting") will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company's common stock as of the close of business on April 14, 2026 will be entitled to vote at the Annual Meeting. Additional information regarding the Annual Meeting will be provided in the Company's proxy statement. Because the date of the Annual Meeting has been advanced by more than thirty (30) days from the anniversary
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quanterix CorporationSCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)
- INSIDERSEC Form 3 filed by new insider Char Daniel3 - Quanterix Corp (0001503274) (Issuer)
- INSIDERChief Operating Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 549 shares, increasing direct ownership by 3% to 31,271 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERNew insider Miller Michael Francis claimed ownership of 30,262 shares (SEC Form 3)3 - Quanterix Corp (0001503274) (Issuer)
- INSIDERChief Financial Officer Sriram Vandana covered exercise/tax liability with 645 shares and converted options into 1,833 shares, increasing direct ownership by 5% to 27,428 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- SECSEC Form S-8 filed by Quanterix CorporationS-8 - Quanterix Corp (0001503274) (Filer)
- SECSEC Form 10-K filed by Quanterix Corporation10-K - Quanterix Corp (0001503274) (Filer)
- SECQuanterix Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Quanterix Corp (0001503274) (Filer)
- PRQuanterix Releases Financial Results for the Fourth Quarter and Full Year 2025Reports $43.9 million in revenue and cash balance of $122 million Company expects to achieve cash flow breakeven during 2026 Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. "I am thrilled to be joining Quanterix at a time when the company is well-positioned to deliver long-term growth," said Everett Cunningham, President & CEO of Quanterix. "During the fourth quarter, we exceeded our revenue expectations, we continued to move the company closer to profitability, and we achieved key milestones in our Alzheimer's Diagnos
- PRLucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities NationwideCollaboration Aims to Expand Access to Early Detection of Potential Disease Marker Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the goals of both organizations to provide non-invasive, easily accessible testing in the general public. According to the Alzheimer's Association, an est
- PRQuanterix to Participate in Upcoming Investor ConferencesQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March: 46th Annual TD Cowen Healthcare Conference Format: Fireside chat and one-on-one meetings Date: Wednesday, March 4, 2026 Time: 11:50 am ET Webcast: Click here Leerink Global Healthcare Conference 2026 Format: Fireside chat and one-on-one meetings Date: Monday, March 9, 2026 Time: 1:00 pm ET Webcast: Click here Interested parties may access a live and recorded webcast of the fireside chats on the Investors section of the company's we
- PRQuanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 79
- INSIDERChief Financial Officer Sriram Vandana converted options into 777 shares and covered exercise/tax liability with 271 shares, increasing direct ownership by 2% to 26,240 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quanterix CorporationSCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)
- INSIDERChief Financial Officer Sriram Vandana covered exercise/tax liability with 4,395 shares, decreasing direct ownership by 5% to 81,618 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- PRQuanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease DetectionSubmission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix's LucentAD® Complete LDT Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer's disease (AD). This submission represents a significant milestone in the Company's mission to provide superior, non-invasive, high-performance diagnostic tools to aid in the evaluation of patients with cognitive symptoms for possible AD. The multi-analy
- INSIDERSEC Form 4 filed by President and CEO Cunningham Everett4 - Quanterix Corp (0001503274) (Issuer)